Cargando…
Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion
Due to their lower production cost compared with monoclonal antibodies, single-chain variable fragments (scFvs) have potential for use in several applications, such as for diagnosis and treatment of a range of diseases, and as sensor elements. However, the usefulness of scFvs is limited by inhomogen...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151396/ https://www.ncbi.nlm.nih.gov/pubmed/28994732 http://dx.doi.org/10.3390/molecules22101695 |
_version_ | 1783357143566516224 |
---|---|
author | Fukuda, Natsuki Noi, Kentaro Weng, Lidong Kobashigawa, Yoshihiro Miyazaki, Hiromi Wakeyama, Yukari Takaki, Michiyo Nakahara, Yusuke Tatsuno, Yuka Uchida-Kamekura, Makiyo Suwa, Yoshiaki Sato, Takashi Ichikawa-Tomikawa, Naoki Nomizu, Motoyoshi Fujiwara, Yukio Ohsaka, Fumina Saito, Takashi Maenaka, Katsumi Kumeta, Hiroyuki Shinya, Shoko Kojima, Chojiro Ogura, Teru Morioka, Hiroshi |
author_facet | Fukuda, Natsuki Noi, Kentaro Weng, Lidong Kobashigawa, Yoshihiro Miyazaki, Hiromi Wakeyama, Yukari Takaki, Michiyo Nakahara, Yusuke Tatsuno, Yuka Uchida-Kamekura, Makiyo Suwa, Yoshiaki Sato, Takashi Ichikawa-Tomikawa, Naoki Nomizu, Motoyoshi Fujiwara, Yukio Ohsaka, Fumina Saito, Takashi Maenaka, Katsumi Kumeta, Hiroyuki Shinya, Shoko Kojima, Chojiro Ogura, Teru Morioka, Hiroshi |
author_sort | Fukuda, Natsuki |
collection | PubMed |
description | Due to their lower production cost compared with monoclonal antibodies, single-chain variable fragments (scFvs) have potential for use in several applications, such as for diagnosis and treatment of a range of diseases, and as sensor elements. However, the usefulness of scFvs is limited by inhomogeneity through the formation of dimers, trimers, and larger oligomers. The scFv protein is assumed to be in equilibrium between the closed and open states formed by assembly or disassembly of VH and VL domains. Therefore, the production of an scFv with equilibrium biased to the closed state would be critical to overcome the problem in inhomogeneity of scFv for industrial or therapeutic applications. In this study, we obtained scFv clones stable against GA-pyridine, an advanced glycation end-product (AGE), by using a combination of a phage display system and random mutagenesis. Executing the bio-panning at 37 °C markedly improved the stability of scFvs. We further evaluated the radius of gyration by small-angle X-ray scattering (SAXS), obtained compact clones, and also visualized open–close dynamics of these scFvs by high-speed atomic force microscopy (HS-AFM), revealing that one of the compact clones was biased to the closed state. Finally, nuclear magnetic resonance (NMR) analysis revealed that peak intensity and line width became homogeneous, supporting that dynamic features and/or formation of oligomers was improved in the thus-obtained clone. These findings should contribute to the future industrial and therapeutic use of scFvs. |
format | Online Article Text |
id | pubmed-6151396 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61513962018-11-13 Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion Fukuda, Natsuki Noi, Kentaro Weng, Lidong Kobashigawa, Yoshihiro Miyazaki, Hiromi Wakeyama, Yukari Takaki, Michiyo Nakahara, Yusuke Tatsuno, Yuka Uchida-Kamekura, Makiyo Suwa, Yoshiaki Sato, Takashi Ichikawa-Tomikawa, Naoki Nomizu, Motoyoshi Fujiwara, Yukio Ohsaka, Fumina Saito, Takashi Maenaka, Katsumi Kumeta, Hiroyuki Shinya, Shoko Kojima, Chojiro Ogura, Teru Morioka, Hiroshi Molecules Article Due to their lower production cost compared with monoclonal antibodies, single-chain variable fragments (scFvs) have potential for use in several applications, such as for diagnosis and treatment of a range of diseases, and as sensor elements. However, the usefulness of scFvs is limited by inhomogeneity through the formation of dimers, trimers, and larger oligomers. The scFv protein is assumed to be in equilibrium between the closed and open states formed by assembly or disassembly of VH and VL domains. Therefore, the production of an scFv with equilibrium biased to the closed state would be critical to overcome the problem in inhomogeneity of scFv for industrial or therapeutic applications. In this study, we obtained scFv clones stable against GA-pyridine, an advanced glycation end-product (AGE), by using a combination of a phage display system and random mutagenesis. Executing the bio-panning at 37 °C markedly improved the stability of scFvs. We further evaluated the radius of gyration by small-angle X-ray scattering (SAXS), obtained compact clones, and also visualized open–close dynamics of these scFvs by high-speed atomic force microscopy (HS-AFM), revealing that one of the compact clones was biased to the closed state. Finally, nuclear magnetic resonance (NMR) analysis revealed that peak intensity and line width became homogeneous, supporting that dynamic features and/or formation of oligomers was improved in the thus-obtained clone. These findings should contribute to the future industrial and therapeutic use of scFvs. MDPI 2017-10-10 /pmc/articles/PMC6151396/ /pubmed/28994732 http://dx.doi.org/10.3390/molecules22101695 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fukuda, Natsuki Noi, Kentaro Weng, Lidong Kobashigawa, Yoshihiro Miyazaki, Hiromi Wakeyama, Yukari Takaki, Michiyo Nakahara, Yusuke Tatsuno, Yuka Uchida-Kamekura, Makiyo Suwa, Yoshiaki Sato, Takashi Ichikawa-Tomikawa, Naoki Nomizu, Motoyoshi Fujiwara, Yukio Ohsaka, Fumina Saito, Takashi Maenaka, Katsumi Kumeta, Hiroyuki Shinya, Shoko Kojima, Chojiro Ogura, Teru Morioka, Hiroshi Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion |
title | Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion |
title_full | Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion |
title_fullStr | Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion |
title_full_unstemmed | Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion |
title_short | Production of Single-Chain Fv Antibodies Specific for GA-Pyridine, an Advanced Glycation End-Product (AGE), with Reduced Inter-Domain Motion |
title_sort | production of single-chain fv antibodies specific for ga-pyridine, an advanced glycation end-product (age), with reduced inter-domain motion |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6151396/ https://www.ncbi.nlm.nih.gov/pubmed/28994732 http://dx.doi.org/10.3390/molecules22101695 |
work_keys_str_mv | AT fukudanatsuki productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT noikentaro productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT wenglidong productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT kobashigawayoshihiro productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT miyazakihiromi productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT wakeyamayukari productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT takakimichiyo productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT nakaharayusuke productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT tatsunoyuka productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT uchidakamekuramakiyo productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT suwayoshiaki productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT satotakashi productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT ichikawatomikawanaoki productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT nomizumotoyoshi productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT fujiwarayukio productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT ohsakafumina productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT saitotakashi productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT maenakakatsumi productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT kumetahiroyuki productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT shinyashoko productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT kojimachojiro productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT ogurateru productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion AT moriokahiroshi productionofsinglechainfvantibodiesspecificforgapyridineanadvancedglycationendproductagewithreducedinterdomainmotion |